Modern biopharma firms are adapting their R&D investment strategies in response to challenges such as the impending $300 ...
Novartis is buying Myricx to internalize an NMTi-based ADC payload platform intended to expand ADC applicability and ...
As advanced therapies scale, manufacturers are rethinking how they bring products to market and who they rely on to get there. In today's Pharmaceutical Executive Daily, AlzeCure Pharma announces a ...
It is also why I have spent over fifteen years building around a conviction the healthcare industry still resists: when ...
Zymeworks will pay $17.00/share (~$929M) for Theravance, prioritizing Yupelri-linked profitability and planned post-close ...
It was a jarring experience that stemmed from a startlingly common misconception: that adults don't get T1D; however, she is ...
For pharmaceutical executives, the transition from just extending to fully optimizing life is a defining commercial ...
Resilient field models emphasize continuous territory coverage via agile deployment, blending scalable virtual reach with ...
In today's Pharmaceutical Executive Daily, the FDA approves Gilead's Trodelvy for the first-line treatment of metastatic ...
"Direct-to-patient isn't merely a new distribution channel; it's a strategic imperative for brand differentiation and market access. When executed well, it enables manufacturers to expand patient ...
Pharmaceutical Executive: How will targeted onshoring impact pharma’s domestic manufacturing? Ryan Last: Targeted reshoring ...
A July 17 response deadline requires documentation of trial-site governance in China, emphasizing due diligence, data protection controls, and monitoring of compliance at Xinjiang and PLA-affiliated ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results